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Dose Fractionation Effects in Primary and Metastatic
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Gregorius P. M. Luyten2
PURPOSE. To investigate the effects of split-dose irradiation on
primary and metastatic uveal melanoma cell lines, with a clo-
nogenic survival assay.
METHODS. Appropriate cell concentrations of four primary and
four metastatic human uveal melanoma cell lines were cultured
for irradiation with single doses and with two equal fractions
separated by 5 hours. After irradiation, colony formation was
allowed for 7 to 21 days. Two cutaneous melanomas were also
tested for comparison. All survival curves were analyzed using
the linear quadratic (LQ) model. Specific parameters for the
intrinsic radiosensitivity (-component, SF2), for the capacity
of repair of DNA damage (-component), as well as the /
ratio were calculated.
RESULTS. After single-dose irradiation a wide range in the values
of the - and -component was obtained for both primary and
metastatic uveal melanomas, which resulted in a wide range of
/ ratios. In contrast, calculations based on split-dose data,
with which the -component could be estimated independent
of the -component, indicated that estimates for the capacity
of sublethal DNA damage repair was very similar in all cell
lines. This indicated that intrinsic factors dominated the radio-
sensitivity of these cell lines. Split-dose irradiation had little
influence on the intrinsic radiosensitivity (-component), but
cell survival increased for all cell lines. For the two cutaneous
melanomas comparable split-dose results were obtained.
CONCLUSIONS. For both primary and metastatic uveal melanoma
cell lines, data from single and fractionated doses indicate large
variations in radiosensitivity, which are mainly dominated by
the intrinsic radiosensitivities. Doses of approximately 8 Gy in
five fractions would be sufficient to eradicate 109 cells (approx-
imately 1 cm3) of the most radioresistant tumor cell lines, but
this schedule is an overkill for the radiosensitive tumor cell
lines. Based on specific morphologic and histologic tumor
markers, more individualized dose fractionation schedules
could improve the therapeutic ratio for uveal melanomas. (In-
vest Ophthalmol Vis Sci. 2003;44:4660–4664) DOI:10.1167/
iovs.03-0151
For small and medium-sized uveal melanomas, radiotherapyis the first choice of treatment. Large-dose fractions of 10 to
12 Gy offer patients an eye- and vision-sparing alternative to
enucleation. However, radiotherapy-related acute and late oc-
ular complications have been reported.1,2 Reduction of these
side effects and improvement of the therapeutic ratio could be
achieved by a better understanding of the radiosensitivity and
capacity for DNA damage repair of these tumors. So far, only
limited information on the cellular radiosensitivity of uveal
melanoma cell lines is available.3–5 In a recent publication large
differences in the intrinsic cellular radiosensitivity were dem-
onstrated for primary and metastatic human uveal melanoma
cell lines.6 The data also pointed to large differences in the
capacity for repair of radiation-induced DNA damage, justifying
a more refined study with the use of split-dose irradiation.
In this article we present single-dose and split-dose data for
cell survival curves analyzed with the linear quadratic (LQ)
model.7–9 This provides information on the intrinsic radiosen-
sitivity and repair capacity of these uveal melanoma cell lines.
In the LQ model, the -component is regarded as a suitable
parameter for the intrinsic radiosensitivity. An alternative way
of expressing the radiosensitivity is the surviving fraction at 2
Gy (SF2).
10–12 When a single dose of X-rays is divided into two
fractions separated by an interval of several hours, an enhance-
ment of survival occurs. The magnitude of this recovery, inter-
preted as a reflection of the repair of sublethal DNA damage
induced by the first dose, can be expressed by the -compo-
nent in the LQ model.
MATERIALS AND METHODS
Cell Lines and Culture Conditions
Four primary and four metastatic uveal melanoma cell lines were used
throughout this study. Two cutaneous melanoma cell lines were also
tested for comparison. Details of the cell lines and culture conditions
have been described previously.6 A few adjustments were made in
comparison with the previous study. Cells were plated with a range of
increasing concentrations and incubated for 2 hours instead of over-
night, to allow cell attachment before radiation commenced. Over-
night incubation for cell attachment is not appropriate for cell lines
with short doubling times, as indicated in this study. For some cell lines
(OCM-1, 92-1, OMM-1, and Bowes) higher cell concentrations were
also used in this study, particularly after the higher doses, to increase
colony numbers and hence to obtain more reliable data
Irradiation and Clonogenic Assay
Technical details of the irradiation procedure and the colony assay
have been described previously.6 Single doses of 0 to 10 Gy were given
with one six-well plate per dose point containing two consecutive cell
concentrations. In the dose fractionation experiment the total dose
was split in two equal fractions with a time interval of 5 hours. An
interval of 5 hours is sufficient for maximum repair of DNA damage
without substantial cell cycle progression.13,14 For the split dose study
a separate set of six-well plates was used again with one plate per dose
point containing two consecutive cell concentrations. Both single and
fractionated irradiations were performed in conjunction on the same
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day. After irradiation, cells were incubated for colony formation. Slow-
growing cell lines (92-1) were incubated for 21 days instead of the
standard 7 days (OCM-1, MelSK28, Bowes) or 14 days (Mel 202, OMM
2-2, OMM 2-3, OMM 2-6, Mel 270, OMM-1) to achieve sufficient colony
formation.
Once the colonies reached an appropriate size they were fixed and
counted, as published previously.6
Data Analysis
Cell survival curves were obtained for each cell line by analyzing the
surviving fractions with the linear quadratic (LQ) model, as described
in detail previously.6 For both single-dose and split-dose irradiations
cell survival curves were averaged from at least three repeat experi-
ments per cell line and with two different cell concentrations per dose
point (Table 1). The -coefficients and the SF2 were calculated as
estimates of the intrinsic radiosensitivity. Along similar lines, -coeffi-
cients, which represent the capacity for repair of sublethal DNA
damage, were calculated. Both the - and -components are cell- and
tissue-specific and were used to derive the / ratio, the dose at which
the contribution of the linear and the quadratic component are equal.
Low / ratios (5 Gy) provides a “curvy” cell survival curve for
radiosensitive cells, with a relatively low -component, whereas higher
/ ratios give less curvy cell survival curves, indicative of cells with a
relatively high -component. In addition, cells displaying low /
ratios are spared by dose fractionation, whereas opposite effects are
seen in cells with high / ratios.
For very steep cell survival curves representing radiosensitive cells,
the correspondingly low -component and SF2 dominate these curves,
which makes it difficult to establish reliable -coefficients. In such
cases large -components can be overlooked.12,15 A low plating effi-
ciency would hamper the analysis even further, because of the small
dose range for which cell survival could be measured.15 To overcome
this problem, the use of the split-dose method provides a much more
reliable estimate for the -component. Based on the LQ-model it is
predicted that the survival recovery ratio, the ratio of split-dose and
single-dose cell survival, increases progressively with dose per frac-
tion.16 There is a linear relationship between the recovered ratio and
the dose per fraction d, calculated as: recovered ratio (RR) 
exp(2d2) which converts into ln(RR)  2d2.
In this formula, d is equal doses per fraction in a split-dose exper-
iment—a split of d  d (i.e., 1  1 Gy, 2  2 Gy, etc.). The slope of
this linear relationship provides an estimate of the -component,
termed RR, which is derived independent of the -component. It was
argued that at least four different dose levels were required for a
proper estimate of the slope of this linear relationship.17 In this study,
all split-dose experiments were performed in a standard manner at six
different dose levels. The RR values presented in Table 1 are averages
of at least three independent experiments per cell line with two
different cell concentrations per experiment.
Sulforhodamine B Assay
The cell-doubling times were determined with the sulforhodamine B
(SRB) assay, which is a colorimetric and nondestructive assay.18 Cells
were grown at 37°C in 96-well plates with lanes of eight wells con-
taining cell concentrations of 100, 250, 500, 1000, 2500, and 5000
cells/mL and 200 L medium/conditioned medium (1:1 vol/vol) per
well. For each consecutive day, excluding Sundays, up to 7 days a
separate plate was used. In each plate a lane of eight wells with
medium only acted as the control. At harvest the medium was removed
and cells were washed three times with distilled water. Cells were
fixed with 10% trichloroacetic acid (TCA) solution for 1 hour at 4°C,
using 200 L per well. The plates were washed five times with distilled
water, air dried overnight and kept at 4°C. All plates were stained
simultaneously for 2 hours adding 50 L per well of a 0.4% SRB
solution in 1% acetic acid. Plates were washed five times in 1% acetic
acid to remove unbound SRB. Per well 150 L Tris (10 mmol/L) was
added and kept overnight at room temperature to dissolve the bound
SRB. The following day, the optical density of the dye was measured in
each well at 540 nm using a spectrophotometer (Bio-Rad, Hercules,
CA). For each lane of eight wells, the optical density was averaged,
omitting the highest and lowest value and subtracting the averaged
control value. For each cell concentration the logarithmic values for
the mean optical densities, expressed in arbitrary units and plotted as
a function of time, gave straight lines. In a statistical analysis program
TABLE 1. Parameters for Uveal and Cutaneous Melanomas after Single and Fractionated Doses of X-Irradiation
Cell Type Plating Eff. (%)
Cell-Doubling
Time (h)  (Gy1)  (Gy2) / (Gy) SF2 RR (Gy
2) /RR (Gy)
Uveal melanoma
OCM-1 (100–6,400)* 29.4  2.3† 18.1  0.4 0.153 0.047 3.5  0.5 0.61 0.039 3.9
29.9  3.0‡ 0.154 0.66
Mel 270 (800–25,600) 9.4  1.0 42.7  1.3 0.534 0.027 20.8  1.6 0.31 0.031 17.5
8.8  1.2 0.451 0.37
OMM 2-2 (200–6,400) 42.2  3.7 28.7  1.6 0.436 0.092 4.7  0.5 0.29 0.048 9.2
43.1  2.7 0.439 0.34
OMM 2-3 (400–12,800) 18.5  4.1 36.4  2.6 0.364 0.039 10.3  1.6 0.41 0.041 8.9
18.5  4.0 0.341 0.47
OMM 2-6 (400–12,800) 9.2  0.6 35.2  1.7 0.330 0.046 8.8  2.0 0.43 0.034 9.6
9.6  0.6 0.365 0.45
Mel 202 (400–25,600) 32.1  2.8 25.1  0.7 0.274 0.035 10.3  3.0 0.50 0.032 8.5
31.5  1.9 0.250 0.56
92-1 (400–51,200) 11.1  1.2 47.3  2.0 0.860 0.010 84.5  28.4 0.17 0.037 23.2
10.2  1.8 0.833 0.19
OMM-1 (800–204,800) 5.8  0.9 37.5  3.0 0.521 0.042 14.1  2.6 0.30 0.024 21.3
5.4  0.7 0.557 0.30
Cutaneous melanoma
MelSK28 (200–6,400) 26.7  1.3 16.9  1.2 0.155 0.053 3.3  0.6 0.59 0.029 5.3
26.0  1.8 0.115 0.66
Bowes (100–12,800) 28.7  6.0 18.5  0.3 0.353 0.114 3.7  1.2 0.34 0.062 5.7
26.7  5.9 0.332 0.36
Data in  expressions are the mean  SEM. Eff., efficiency.
* Range of cell number plated per well.
† Single-dose data.
‡ Data for two equal fractions with a time interval of 5 hours.
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(SlideWrite Plus; Advanced Graphics Software, Inc., Encinitas, CA),
linear regression analysis was used for computer fitting of lines to the
data points. Examples of optical densities as a function of time are
presented in Figure 1. From the slopes of these lines, the cell-doubling
time was calculated. Data for the lowest cell concentration were
occasionally unreliable, producing lines with very shallow slopes,
indicating a very slow cell growth. For the highest cell concentrations
and the longer growth periods, arbitrary units in excess of 2000 were
ignored, because it appeared to be the maximum reliable value in this
assay. Beyond this value, cell growth was not logarithmic anymore and
diminished because of too high cell densities in the wells, as seen in
Figure 1 for OCM-1. Growth curves for the high cell concentrations
based on only two or three time points were ignored. Values for the
slopes of the growth curves from the intermittent cell concentrations
were averaged and used to calculate a cell-doubling time for each
experiment. The overall cell-doubling time for each cell line was an
average obtained from at least three independent experiments.
RESULTS
Cell-Doubling Time
The cell-doubling times for the uveal and cutaneous melano-
mas are presented in Table 1. They range from 16.9 hours
(MelSK28) to 47.3 hours (92-1). Examples of growth curves for
fast- and slow-growing cell lines (OCM-1 and Mel 270, respec-
tively) are presented in Figure 1. The short doubling times for
some of these cell lines justified a short attachment period after
plating before irradiation commenced. The short doubling
times for some of these cell lines could have influenced the
outcome of dose fractionation because of cell growth between
application of fractions. For the fast-growing cell lines no
significant cell growth was determined with the SRB assay
within 6 hours after plating (data not shown).
Plating Efficiency
The plating efficiencies, as obtained from the surviving frac-
tions after a dose of 0 Gy, ranged from 5.4% (OMM-1) to 43.1%
(OMM 2-2) with no significant differences in cell concentration
for both single and fractionated doses (P  0.16). Hence, for
each cell line data obtained for the two consecutive cell con-
centrations were combined. Also the plating efficiencies be-
tween the single and fractionated doses did not differ signifi-
cantly (P  0.38; Table 1).
Cell Survival Curve Parameters
Cell survival curves after single and fractionated doses are
presented in Figure 2 for the uveal and cutaneous melanomas.
The parameters associated with these survival curves are pre-
sented in Table 1. A wide range of -coefficients was found
after single doses with very high and low values for OCM-1
cells (0.153 Gy1) and for 92-1 cells (0.860 Gy1), respec-
tively. Estimates for the -coefficients, indicative of intrinsic
radiosensitivity, are reflected in the SF2, with high values for
radioresistant cell lines and lower values for the more radio-
sensitive cell lines. After single doses, the -coefficients ranged
from 0.027 to 0.053 Gy2, except for OMM 2-2 cells and the
cutaneous melanoma Bowes cells, which produced much
larger -coefficients (0.10 Gy2; Table 1) indicating less
efficient repair of DNA damage. This resulted in low / ratios
of 3.5 to 4.7 Gy (OCM-1, OMM 2-2, SK28, and Bowes) and
higher / ratios (8.8 Gy) for the other primary and meta-
static uveal melanomas. The exception was cell line 92-1 with
a large -component of 0.86 Gy1, whereas the -component
was very low, resulting in a high / ratio of 84.5 Gy. The low
SF2 indicates that this cell line is very radiosensitive.
As expected, after split-dose irradiation the -components
(initial DNA damage) remained very similar to those obtained
after single doses with only minor deviations of 10%. For cell
lines Mel270 and MelSK28, larger deviations of 15.4% and
25.5%, respectively, were obtained for the -component. As
expected, the SF2 increased after split-dose irradiation for all
but one cell line, OMM-1. This increment in SF2 is a reflection
of repair of sublethal DNA damage between application of the
two fractions.
The alternative method for obtaining a more accurate esti-
mate for the -component independent of the -component,
as reported by Peacock et al.,15,17 resulted in RR values similar
to those obtained with single-dose survival curves for most of
the cell lines (Table 1). Only for cell lines OMM 2-2, 92-1, and
OMM-1, the RR values deviated substantially, which resulted
in much higher (OMM 2-2 and OMM-1) or lower / ratios
(92-1).
DISCUSSION
The single-dose data, presented in this article on the radiosen-
sitivity for primary and metastatic human uveal melanoma cell
lines, are more refined than those published earlier.6 These
earlier results could have been influenced by a confounding
factor such as cell growth during overnight attachment. The
short cell-doubling time for some of the cell lines indicated that
a short attachment period of 2 hours before commencement of
irradiation was more appropriate than overnight attachment.
Apart from reduced plating efficiencies for nearly all cell lines,
this shorter attachment period also produced much higher
FIGURE 1. Growth curves for fast- and slow-growing cell lines (OCM-1 and Mel 270, respectively), obtained with the SRB assay. The slope of the
curves is an estimate for the cell-doubling time. Increasing cell concentrations of 100 (F), 250 (ƒ), 500 (Œ), 1000 (E), 2500 (f), and 5000 cells/mL
() were used. Cells were cultured in standard medium in the presence of conditioned medium (1:1 vol/vol).
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-components for OCM-1 cells and Bowes cells, whereas for
the cell types OMM 2–2, OMM 2-3, OMM 2-6, and MelSK28 the
-coefficient increased. This resulted in low / ratios of ap-
proximately 3.5 Gy for the fast-growing cell lines. In this study,
better estimates for the single-dose cell survival curves of 92-1
cells and OMM-1 cells could be obtained, because of higher cell
concentrations at the higher dose points and a longer postra-
diation incubation time of 21 days (92-1). This resulted in more
reliable data at higher doses, explaining the differences in
parameters with previously published data for these two cell
lines.6
Cells displaying a low / ratio, which is indicative of a
sparing effect after dose fractionation, require large doses per
fraction for effective tumor treatment. In this instance little
benefit in therapeutic ratio was seen, because the late-respond-
ing normal tissues also displayed low / ratios in the range of
1 to 5 Gy. For cell lines with higher / ratios (6 Gy),
conventional doses per fraction of 2 Gy should provide thera-
peutic gain with an increased probability of tumor cure and
sparing of late-responding normal tissues.
In this study, cell lines Mel270, 92-1, and OMM-1 displayed
low plating efficiencies and high  values after single-dose
irradiation, and therefore estimates for the -coefficient could
be inaccurate.12,15 The RR values for all cell lines displayed a
narrow range of 0.024 Gy2 (OMM-1) to 0.047 Gy2 (OMM
2-2), which was much smaller than that obtained from analysis
of the single-dose cell survival curves (Table 1). It appeared
that for cell lines OMM 2-2, 92-1, and OMM-1 the RR values
differed substantially from those obtained after single-dose ir-
radiation, but were now within the range of the other cell
lines. A much lower RR value was unexpectedly also found for
OMM 2-2 cells compared with the original -component after
single-dose irradiation. Only for Bowes cells was the RR value
(0.0622 Gy2) outside this range, but it was approximately half
the value obtained from the single-dose cell survival curve. This
had an effect on the new /RR ratios with that for OMM 2-2
cells in the same range as for the other metastatic cell lines
OMM 2-3 and OMM 2-6. All three cell lines derived from the
same primary melanoma Mel 270 (Table 1). Also for cell line
92-1 and OMM-1, the /RR ratios changed to approximately 22
Gy. The new /RR ratios for the cutaneous melanomas in-
creased to approximately 5.5 Gy.
For a number of human tumor cell lines, a linear relation-
ship between ln(RR) and fraction dose (d), as predicted by the
LQ model, has been demonstrated,15,17,19,20 which resulted in
a RR independent of the -component. It was also argued that
an estimate of the -component could be obtained indepen-
dent of the -component by low-dose irradiation.15,17 At our
institute, facilities for low-dose irradiation were not available,
and hence an estimate for an independent -component could
not be achieved.
The RR values are in the normal range for tumor cell lines
and differ only by a factor of 2. This indicates that the capacity
for repair of sublethal DNA damage is fairly constant for all cell
lines investigated. This implies that the variations in radiosen-
sitivity of these melanoma cell lines are more determined by
the -components—that is, the intrinsic radiosensitivity—and
to a lesser extent by contributions of sublethal DNA damage
repair. This has implications for clinically relevant dose frac-
tionation schedules, because cell types OCM-1, Mel 202, and
MelSK28 with low -components and high SF2s would neces-
sitate relatively large doses of approximately 8 Gy in five
fractions for effective elimination of a tumor containing ap-
proximately 109 cells. In contrast, for cell type 92-1, doses of
approximately 4 Gy in five fractions should be sufficient for
effective eradication, with a beneficial effect of limiting ad-
verse normal tissue toxicity.
In low-dose-rate (LDR) brachytherapy, cell survival is en-
tirely determined by the -component—that is, the intrinsic
radiosensitivity, due to repair of sublethal DNA damage during
the long exposure times and hence the absence of the -com-
ponent. For the two most extreme -components in this study,
elimination of 109 cells of tumor type OCM-1 would require
approximately 135 Gy, whereas tumor type 92-1 would require
FIGURE 2. Cell survival curves for various primary (OCM-1, Mel 270, Mel 202, 92-1) and metastatic (OMM 2-2, OMM 2-3, OMM 2-6, OMM-1) human
uveal melanomas in comparison with cutaneous melanomas (MelSK28, Bowes) after single doses of X-rays (solid lines) and split-dose irradiation
involving two equal fractions with an interfraction interval of 5 hours (dotted lines). Cells were cultured in standard medium in the presence of
conditioned medium (1:1 vol/vol). If standard errors are not present, they fall within the symbol. Data indicate / ratios ( SEM).
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only approximately 24 Gy. With a dose rate of approximately
1 Gy/hour this indicates an exposure time of approximately 5.6
days for OCM-1 cells, whereas cells of tumor type 92-1 would
be eliminated in 1 day.
Caution should be used in translating these in vitro data
directly into clinical practice. However, studies have shown
that for many tumor cell lines, in vitro data and especially
parameters related to the initial part of the cell survival curve,
such as the -component and SF2, seem to correlate with the
clinical radioresponsiveness of human tumors.21 That the radi-
osensitivity of these uveal melanomas is mainly determined by
the intrinsic radiosensitivity should encourage a study on spe-
cific morphologic and histologic tumor markers, which could
be applied in the clinical situation without tumor biopsy. Based
on these morphologic markers, tumor classification would be-
come a possibility, leading to more individualized dose frac-
tionation schedules.
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